INTRODUCTION
We previously reported that intravenous steroids reduce the severity of bronchopulmonary dysplasia (BPD) in very low birth weight (VLBW) infants. 1 BPD is defined as either chronic lung disease requiring supplemental oxygen at 28 days of age or at 36 weeks postconceptional age that develops in premature neonates treated with oxygen and positive pressure mechanical ventilation for a primary lung disorder.
Intravenous steroids improve the course of BPD in VLBW infants but are associated with adverse effects including hypertension, hyperglycemia, and adrenal suppression. 1, 2 The inhaled route of delivery of steroids may maximize pulmonary effects while minimizing systemic effects as documented by the clinical success in delivering steroids through metered-dose inhalation to young asthmatic patients. 3, 4 Initial studies examining inhaled steroids for the treatment of BPD in ventilator-dependent VLBW infants utilized both nebulized and metered-dose inhaled steroids, which appeared to be of some benefit for these infants. 5 -8 Delivery of inhaled steroids through a metered-dose inhaler system was demonstrated to be more efficient in two different laboratory models by O'Callaghan et al. 9 and Rozycki et al. 10 Because the number of studies done with inhaled steroids is small, the benefits and possible adverse effects of inhaled steroids used for the treatment of BPD in ventilator-dependent VLBW infants are not well known. In addition, limited data directly compare the effects of inhaled versus intravenous steroids.
Therefore, we conducted a randomized prospective clinical trial to evaluate the efficacy and safety of inhaled versus intravenous steroids in ventilator-dependent VLBW infants. We hypothesized that inhaled steroids are equally efficacious as intravenous steroids for short-term pulmonary improvement in ventilator-dependent VLBW infants with BPD. We further hypothesized that adverse effects are reduced when using the inhaled route of delivery compared to intravenous administration.
METHODS
The study was approved by the Institutional Review Board of Children's Hospital of Buffalo. Informed consent was obtained from all parents.
Patient Population
Patients eligible for enrollment met the following criteria: birth weight 1500 g, gestational age 30 weeks, and conventional ventilator dependence at 12 to 21 days of age with a rate 15, and FiO20.30 with a persistence of these ventilator settings for a minimum of 72 hours before entry into the study. Infants were ineligible if they were on high-frequency oscillatory ventilation
OBJECTIVE:
Intravenous steroids improve the respiratory course in ventilator -dependent preterm infants but have adverse effects. We hypothesized that inhaled steroids would be as effective, but with less systemic effects.
STUDY DESIGN:
We conducted a randomized, prospective trial comparing inhaled beclomethasone, either 400 or 800 g / d, to intravenous dexamethasone in preterm infants dependent on conventional mechanical ventilation and supplemental oxygen at 2 weeks of age.
RESULTS:
Seventy -eight infants were randomized. By day three of therapy, the intravenous steroid group had significantly decreased ventilator and oxygen requirements compared to either inhaled group. The inhaled 800 -g /d group trended toward more rapid decreases in ventilator and oxygen requirements than the 400 -g / d group. By day 14, all groups had similar reductions in ventilator and oxygen requirements. The incidence of adverse effects did not differ between groups.
CONCLUSIONS:
In this small, randomized study, inhaled steroids conferred no advantages to intravenous steroids in the management of ventilator -dependent preterm infants. Journal of Perinatology Original Article
(HFOV) due to the inability to administer inhaled medications through the HFOV circuit. Infants were excluded from the study if they had major congenital malformations, culture-positive sepsis, hypertension, which required medical management, persistently patent ductus arteriosus, or hyperglycemia, which required insulin. Infants were also excluded if they had received any postnatal steroid therapy (either inhaled or intravenous) before 12 days of age or before entry in the study. All infants <1500 g birth weight had an endotracheal aspirate obtained on day 7 or 8 of life if intubated. If this culture was positive for yeast or gram-negative bacteria, the infant was ineligible for the study. All inborn patients 29 weeks received surfactant in the delivery room as part of an ongoing clinical study.
Randomization Procedure
Infants enrolled were assigned to one of three groups by random allocation: inhaled beclomethasone at 400 g/d, inhaled beclomethasone at 800 g/d, or intravenous dexamethasone. Before the onset of the study, three sets (one set for each study group) of 27 cards were assembled followed by the placement of one card each into one of 81 opaque envelopes. As infants were enrolled, a card was pulled sequentially and the infant assigned to the appropriate study group. In the case of multiple gestation, all eligible siblings were assigned to the same group to minimize parental anxiety regarding differential treatment of their infants.
Dosing Regimens
The inhaled beclomethasone was delivered through a metereddose inhaler with a spacer device (Aerovent) connected in-line with the ventilator at approximately 50 g per actuation (puff). Between each actuation, the infant was ventilated with four to five hand-bagged breaths delivered by a respiratory therapist at a peak pressure identical to that delivered during mechanical ventilation. The 400-g/d group received four puffs every 12 hours, and the 800-g/d group received four puffs every 6 hours. The beclomethasone was continued until extubation. If the infant successfully extubated, then the same dose that he/she received was administered for 48 hours more. Thereafter, the steroid dose was halved every other day for 6 days, after which the steroid was stopped. After extubation, the inhaled beclomethasone was given using a facemask with the inhaler and spacer device. The intravenous dexamethasone dose followed the regimen established by Avery, 2 a 42-day tapering course, which started with 0.5 mg/ kg per day, divided every 12 hours.
Crossover from either of the inhaled beclomethasone groups to the intravenous dexamethasone group was allowed if, after 4 to 5 days of inhaled beclomethasone, the infants' ventilator and oxygen support had not decreased and the attending neonatologist felt that the infant might benefit from intravenous dexamethasone. However, all data were analyzed according to the original group assignment. All other aspects of management, including the use of methylxanthines and diuretics, were left to the discretion of the attending neonatologist.
Patient Monitoring
Ventilatory settings, specifically rate, mean airway pressure (MAP), peak inspiratory pressure (PIP), positive end expiratory pressures (PEEP), and supplemental oxygen requirement were recorded every 6 hours daily on all enrolled patients starting from 5 days before initiation of steroid therapy and continued daily thereafter, until extubation. We recorded any reintubations. After extubation, the supplemental oxygen requirement was recorded daily until supplemental oxygen was discontinued or patient was discharged. Capillary blood gases were recorded daily from 5 days before initiation of steroid therapy and daily for 1 week thereafter. We monitored blood pressure measurements and heelstick glucose estimation twice a day, and serum electrolytes weekly. Hypertension was defined as a mean arterial blood pressure greater than two standard deviations above the values reported by Tan 11 for similar infants, and requiring medical intervention. Hyperglycemia was defined as two consecutive heelstick glucose estimation greater than 180 mg/dl and requiring medical intervention (insulin or >25% reduction in glucose infusion rate). Daily weights were taken. Length of hospitalization was also recorded. We recorded any episodes of culture-proven or clinically suspected sepsis. Weekly surveillance cultures of urine and endotracheal aspirates were collected.
For babies who completed at least a 10-day course of either inhaled or intravenous steroids, an ACTH stimulation test was done 2 weeks after completion of the steroid course. Infants were given an intravenous bolus of 36 g/kg synthetic ACTH (Cortrosyn, Organon, West Orange, NJ). 12, 13 Morning blood samples for cortisol levels were collected immediately before and 60 minutes after administering ACTH.
The occurrence of the following was also recorded: intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, retinopathy of prematurity, hypertension requiring medical management, gastrointestinal bleed, and death.
Data Analysis
Sample size was determined by assuming a rate of adverse effects (as defined by sepsis, or hyperglycemia or hypertension requiring treatment) of 80% in intravenous steroid-treated infants, based on published data. 1, 14 At 80% power, a sample size of 23 to 24 in each group would be sufficient to show that a difference in adverse effects of 30% or more was significant at p<0.05. To allow for some dropouts we therefore planned to enroll up to 27 infants in each of the three groups. To analyze the response to steroid therapy, we first applied single-factor analysis of variance for repeated measures to determine whether a variable changed over time within a group. If a variable did change with time within a group, the values for that variable were compared by Fisher PLDS to determine at which time they were different from baseline. Two-factor analysis of variance for repeated measures was used to determine if the groups were different from each other. If the groups were different, unpaired t-tests were used to determine at which times they were different. Pre and post study comparisons used chi square, Mann-Whitney, Kruskal-Wallis or unpaired t-test. All values are mean±standard deviation. p0.05 was considered statistically significant.
RESULTS
From July 1994 to July 1996, 314 infants were admitted to the neonatal intensive care unit (NICU) at Children's Hospital of Buffalo with a birth weight 1500 g and gestational age 30 weeks. Of these 314 infants, 30 died before 12 days of life, 163 did not meet the ventilatory and supplemental oxygen requirements, 8 had patent ductus arteriosus, 10 had culture-proven sepsis, 16 received steroid therapy before 12 days of age, and 4 had congenital anomalies. Of the remaining 83 infants, parents of 5 infants refused consent. Of the 78 infants enrolled, 26 were randomized to the 400-g/d beclomethasone group, 25 to the 800-g/d beclomethasone group, and 27 to the intravenous dexamethasone group. (Table 1) The three groups were similar in gestational age, birth weight, gender, race, incidence of pneumothorax, and incidence of treated patent ductus arteriosus (Table 1) . Because we assigned individuals within a set of multiples to the same group, there was a statistically significant difference between the three groups regarding some maternal characteristics, such as the use of maternal steroids and mode of delivery of the infant. All inborn patients 29 weeks received surfactant prophylactically in the delivery room as part of an ongoing clinical study. Hence, all infants were assumed to be at high risk for respiratory distress syndrome (RDS). All outborn infants received surfactant therapy for established RDS. No infant was diagnosed with meconium aspiration syndrome or congenital pneumonia. As was customary in the NICU, all of the infants in the study were started on methylxanthines before initiation of steroid therapy. Forty-two percent of the infants in each group received diuretics at some point during the study.
Prestudy Patient Characteristics
Study Assignments (Table 2) The mean entry age for all three groups was 17±3 days (Table 2) . Nine infants in the 800-g/d beclomethasone group and nine infants in the 400-g/d beclomethasone group crossed over at 31 days (median, range 18 to 62 days of age) and 29 days (median, range 22 to 43 days of age) of age, respectively, and received intravenous steroids. Within-group comparison of crossed over infants versus noncrossed over infants revealed no significant differences in patient characteristics or clinical parameters. 
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Interestingly, crossed over infants tended to receive overall more days of steroid therapy. Several infants were removed from the study: two in the intravenous group due to perceived lack of response, two in the 800-g/d beclomethasone group due to possible sepsis, and four in the 400-g/d beclomethasone group, one each due to possible sepsis, fungal sepsis, necrotizing enterocolitis, and need for HFOV.
Initial Respiratory Changes (Table 3) On the day that steroids were started (baseline), ventilatory pressure differences (PIP-PEEP; an estimate of compliance) were significantly higher in the inhaled 800-g/d group compared to the inhaled 400-g/d group (Table 3 ). All three groups had similar baseline MAP and supplemental oxygen requirements.
By the third day of steroids, the intravenous steroid group had a significant decrease from baseline in MAP, ventilatory pressure differences, and supplemental oxygen requirements. The inhaled 400-g/d group also had a significant decrease from baseline in MAP. By the seventh day of steroids, all three groups had a significant decrease from baseline in MAP and supplemental oxygen requirements. In addition, the inhaled 800-g/d group and intravenous steroid group had significant decreases from baseline in ventilatory zSignificantly different between 400 -and 800 -g groups. xSignificantly different between 400 and IV groups.
pressure differences. By day 14 of treatment, all three groups had significant reductions from baseline in MAP, ventilatory pressure differences, and supplemental oxygen requirements. At day 14 of treatment, there were no significant differences in MAP, ventilatory pressure differences, or supplemental oxygen requirements between the three groups.
Respiratory Outcomes and Length of Stay (Table 4) Durations of mechanical ventilation, supplemental oxygen and hospital stay did not differ between the three groups ( Table 4 ). The number of neonates that required mechanical ventilation and supplemental oxygen use at 28 days of age was similar in all three groups. There was no significant difference in the incidence of BPD between the groups: 75% of neonates in the inhaled 800-g/d group vs. 80% in the inhaled 400-g/d group vs. 85% in the intravenous group.
Adverse Effects (Tables 5 and 6 ) There was a similar number of blood culture positive sepsis in all three groups (Table 5 ). In the intravenous steroid group, the organisms were a gram-negative bacilli, and Enterococcus in two patients. In the inhaled 400-g/d group, the organisms were Adenovirus, Staphylococcus epidermidis, and Candida species in two patients. In the inhaled 800-g/d group, the organisms grown were Enterococcus, Pseudomonas aeruginosa, and Coagulase negative S. epidermidis. No episodes of hyperglycemia receiving insulin therapy occurred in any of the groups.
Baseline mean arterial blood pressures were similar between the groups. By the third day of steroids, the mean arterial blood pressures of the neonates in the intravenous group (53±6 mm Hg) were significantly elevated compared to the 400-g/d inhaled group (45±6 mm Hg, p0.0001), and the 800-g/d inhaled group (48±5 mm Hg, p=0.0015). Similarly, by the seventh day of steroids, the mean arterial blood pressures of the neonates in the intravenous group (55±5 mm Hg) were significantly elevated compared to the 400-g/d inhaled group, (49±6 mm Hg, p=0.0008) and the 800-g/d inhaled group, (49±9 mm Hg, p<0.0066). However, by day 14 of steroids, there was no significant difference in mean arterial blood pressures between the three groups. The mean arterial blood pressure in the intravenous group at day 14 of steroids had decreased to 52±7 mm Hg due to the use of antihypertensive medications and/or a more aggressive tapering schedule whereas the mean arterial blood pressure in both inhaled groups remained fairly constant.
Infants in all three groups with elevated mean arterial blood pressure received antihypertensive medications. Of these, two of the three infants in the inhaled 800-g/d and two of four infants in the inhaled 400-g/d group required antihypertensive medications only after the crossover to intravenous dexamethasone.
The occurrence of necrotizing enterocolitis, retinopathy of prematurity Stage 3 and periventricular leukomalacia was similar in all the groups (Table 6 ). Gastrointestinal bleeding did not occur. There were no deaths in the intravenous steroid group. In the inhaled 800-g/d group, there was one death at 22 days of age due to 
Pseudomonas sepsis. In the inhaled 400-g/d group, there was one death at 21 days of age due to Adenovirus sepsis. The ACTH stimulation test was completed in 24 of the neonates: 10 in the intravenous group, 7 in the 800-g/d inhaled group, and 7 in the 400-g/d inhaled group. In both inhaled groups, 2 of these infants had crossed over to receive intravenous steroids. The baseline cortisol levels before the ACTH stimulation test for the 800-g/d inhaled group (3±2.3 g/dl) and the intravenous group (1.6±1.3 g/dl) were statistically lower than the 400-g/d inhaled group (7.3±4.2 g/dl). However, the response to the ACTH (i.e., relative rise in cortisol level) was similar in all three groups: 12.0±5.7 g/dl in the 400-g/d inhaled group, 15.6±8.5 in the 800-g/d inhaled group, and 10.7±4.6 in the intravenous group, p=0.4081. Post ACTH stimulation cortisol levels were, in the 800-g/d inhaled group 18.4±8 g/dl, in the 400-g/d inhaled group 19.3±5.9 g/dl, and in the IV group 12.3±5.7 g/dl, p=0.0483.
DISCUSSION
The results of our study suggest that inhaled and intravenous steroids are equally efficacious in the management of ventilator-dependent VLBW infants with a similar occurrence of adverse effects.
Acute improvements in ventilatory and supplemental oxygen requirements appeared to occur sooner in the infants receiving intravenous steroids compared to either inhaled group. However, by day 7 of steroid therapy, the inhaled and intravenous groups were similar in MAP requirements as well as in supplemental oxygen need. At the end of 2 weeks of steroid therapy, there was no significant difference between the inhaled and intravenous steroid groups in ventilatory and supplemental oxygen requirements. There were no differences in the need for supplemental oxygen at 28 days of life or at 36 weeks postconceptional age. There were also no differences in several long-term outcomes including duration of mechanical ventilation, duration of supplemental oxygen use or hospital stay.
Based on observations of children with asthma, we hypothesized that VLBW infants who received inhaled steroids would have fewer adverse effects than those who received intravenous steroids. 3, 4 However, our study did not support this conclusion. The incidence of culture proven sepsis, hypertension, or hyperglycemia, commonly reported with the use of intravenous steroids, was similar between the three groups. The incidence of other complications, such as periventricular leukomalacia, advanced retinopathy of prematurity, and necrotizing enterocolitis, which may or may not be related to steroid use, was also similar between the three groups. This finding might suggest that, if any of these adverse effects were attributable to steroid therapy, the occurrence of adverse effects may be independent of route of administration.
There are only two other clinical studies directly comparing inhaled to intravenous steroids in ventilator-dependent VLBW infants. Dimitriou et al. 15 studied 40 preterm infants who had remained either ventilator-or supplemental-oxygen-dependent with no improvement in their respiratory status in a prospective randomized trial. Beginning at a postnatal age of 26 to 27 days, the premature infants were randomized to either 100 g/d inhaled budesonide or intravenous dexamethasone for 10 days. (Budesonide offers a more advantageous therapeutic index as well as a better topical anti-inflammatory to systemic anti-inflammatory ratio but was not available in the United States at the time of our study. 16 ) Similar to our observation, Dimitriou et al. found a longer time to pulmonary improvement for those infants who received inhaled steroids. They also noted no differences in long-term outcomes including duration of mechanical ventilation or duration of supplemental oxygen use. There were no differences in the need for supplemental oxygen at 28 days of life or at 36 weeks postconceptional age. They did not mention length of hospital stay.
Dimitriou et al. also reported similar adverse effects between the intravenous and inhaled steroid groups but to a lesser extent in the inhaled group. They noted six cases of culture-proven sepsis in their intravenous group (all S. epidermidis) compared to one infant from the inhaled steroid group with a skin culture positive for both a Candida species and S. epidermidis. They also noted a significant increase in blood pressure in the intravenous group. They did not comment on the incidence of retinopathy of prematurity or periventricular leukomalacia. Survival until discharge was noted as 18 of 20 in the intravenous group and 19 of 20 in the inhaled group with no comment on cause of death. An ACTH stimulation test was not performed on any of the neonates.
The second study that compared the use of inhaled versus intravenous steroids in ventilator-dependent VLBW infants was done by Groneck et al. 17 They studied the effect of steroids on lung inflammation and pulmonary microvascular permeability. Sixteen ventilator-dependent VLBW infants were enrolled and randomized to receive either 1500 g/d inhaled beclomethasone beginning on day 3 of life or intravenous dexamethasone starting at day 10 of life. Similar to our study, they showed a more immediate response to intravenous rather than inhaled steroids. On day 14 of life, the average supplemental oxygen requirement in the inhaled group was 0.38 compared to 0.23 in the intravenous group. They found a longer duration of mechanical ventilation and supplemental oxygen need in those infants that received inhaled steroids compared to the intravenous group but did not comment on length of hospital stay. The incidence of BPD, which they defined as supplemental oxygen need at 28 days of life, was higher in the inhaled group, 6 of 7 infants, vs. 2 of 9 in the intravenous group. The only adverse effect that was commented on involved the late (>28 days of age) death of one infant in the inhaled group due to necrotizing enterocolitis. An ACTH stimulation test was not performed on any of the neonates.
Although only a subset of our patients received an ACTH stimulation test, we found no strong clinical or biochemical evidence for adrenal suppression. Basal cortisol levels in the 400-g/d beclomethasone group were similar to those reported in historical controls of other studies evaluating the hypothalamic-pituitary-adrenal axis in VLBW infants who had received either placebo or inhaled steroids. 18, 19 Basal cortisol levels in the 800-g/d beclomethasone group were significantly lower than the 400-g/d beclomethasone group. In the intravenous dexamethasone group, basal cortisol levels were even lower than either inhaled group but similar to levels previously reported. 12, 20 Cortisol levels in all three groups increased similarly following ACTH stimulation, but for each group, the mean response was blunted in comparison to that of historical controls. 19 Although there was a trend toward a greater response for infants within the inhaled groups, one must use caution in interpreting these results because approximately 30% of these infants crossed over to intravenous treatment. If one looks only at those infants who did not cross over, the trend is similar. Also, although an increase in cortisol levels in response to ACTH may suggest intact adrenal function, it may also reflect the higher dose of ACTH used in our testing, which has been reported to mask inadequate adrenal function in some preterm infants. 20 There are some limitations to our study design. First, we compared the use of inhaled steroids directly to that of intravenous steroids without a control group. The decision to not include a control group was based on the fact that the use of steroids for BPD was the standard of care offered in many NICUs at the time of our study. Second, our study was not blinded. Although in theory a comparison of two different routes of administration (inhaled versus intravenous) might be masked by administration placebos, the difficulties that this would raise, and the additional unnecessary interventions to the infants, made us decide against a masked design. Third, approximately 35% of the neonates crossed over from the inhaled to the intravenous group, which would make interpretation beyond the crossover point difficult. However, that should not affect our conclusion regarding the short-term efficacy of inhaled steroids as most of the neonates that crossed over did so after receiving at least 14 days of inhaled steroids. The incidence of adverse effects also did not appear to be affected by crossover with the exception of the use of antihypertensive medications. The majority of infants in the inhaled groups that required antihypertensive medications did so after the crossover to systemic steroids. The incidence of adverse secondary outcomes was only 30% in the intravenous group, significantly less than anticipated in our sample size determination. However, the overall incidence of adverse secondary outcomes in the inhaled steroid groups was only slightly less, at 28%. To show whether this 2% difference was statistically significant at p<0.05 with 80% power would require several hundred infants in each group, clearly beyond the scope of this study.
In recent years, there has been increasing evidence suggesting that intravenous steroids given during the neonatal period are associated with long-term developmental impairment. 21, 22 At the time of our study, there were no clinical studies suggesting this possible link, and the use of intravenous steroids was fairly common. Our study was not designed to evaluate long-term outcome. Nevertheless, the similar risk profiles between inhaled and intravenous steroids seen in our study, and the occurrence of systemic effects seen with the use of inhaled steroids (i.e., hypertension) suggest that the long-term neurodevelopmental risk of steroid use is probably independent of route, and that inhaled steroids confer no advantage over intravenous steroids regarding possible neurologic injury.
In conclusion, in the small, randomized study, inhaled steroids conferred no advantages to intravenous steroids in the management of ventilator-dependent VLBW infants. The delayed onset of activity and similar risk profile of inhaled steroids suggests that their effects may be secondary to systemic absorption.
